Patent ID: 9034837
Filing Date: 2015-05-19
Classification: A61K,A61P,C12N

Abstract:
1. A method of treating a hepatitis C virus (HCV)-infected subject who responds poorly to interferon therapy comprising administering an effective amount of an anti-miR-122 oligonucleotide to the subject, wherein (a) the anti-miR-122 oligonucleotide has a length of 7 to 18 nucleotides; (b) the anti-miR-122 oligonucleotide comprises least one LNA nucleotide analogue; (c) the anti-miR-122 oligonucleotide comprises least one phosphorothioate internucleotide linkage; and, (d) the anti-miR-122 oligonucleotide is essentially incapable of recruiting RNase H.